Duvakitug（曾用名TEV’574）是一款潜在“best-in-class”的人源IgG1-λ2单抗，靶向TL1A，又称肿瘤坏死因子（TNF）超家族成员15。TL1A通过与其受体DR3结合，可放大炎症反应并加速IBD相关纤维化的进展。靶向TL1 ...

Science & Technology近日，我院左涛研究员和高翔主任医师团队合作在Gut（IF=23.0）在线发表题为“Fecal phageome transplantation alleviates intermittent ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Investing.com -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)股价在宣布其用于治疗炎症性肠病 ...

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...

Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...